X4 Pharmaceuticals Refinances Hercules Debt With $80 Million K2 Loan Due In 2030
The new facility pushes out a July 2027 maturity, adds a market-value cash covenant from 2027, and lets lenders convert up to $15.0 million into stock.
X4 Pharmaceuticals, which develops and sells treatments for rare blood diseases, retired its Hercules loan on October 7 with an $80.0 million first-tranche loan from K2 HealthVentures, the company said in its quarterly report filed Wednesday. The new debt matures in October 2030, and its lenders can swap up to $15.0 million of principal into stock.
Terms of the K2 loan
The K2 agreement allows term loans of up to $150.0 million. The $80.0 million first tranche arrived October 7; the remaining $70.0 million depends on X4 requesting it and the lenders choosing to approve it.
X4 used substantially all of the proceeds to repay Hercules in full: $75.0 million of principal, $2.8 million of end-of-term fees and $0.8 million of early termination and other fees. The company put the total payoff at about $78.7 million.
Cash interest is the greater of 8.55% or the prime rate plus 1.55%, with an extra 1.0% a year paid in kind. Payments are interest-only through October 1, 2029, followed by principal and interest for 13 months. The interest-only period extends to maturity if X4 achieves first U.S. commercial sales of mavorixafor in chronic neutropenia, among other conditions.
The lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share, subject to certain beneficial ownership limits. The debt is secured by substantially all assets other than intellectual property.
Covenants tied to market value
Starting October 1, 2027, whenever X4's market capitalization is below $800.0 million, it must hold unrestricted cash of at least 75% of its K2 obligations. That threshold falls to 40% once certain conditions are met. Market capitalization stood at $314 million in Wednesday's report-day data, with the stock at $3.24.
A second test starts April 1, 2029: product sales over any three months must equal at least 50% of what the board-approved projections call for.
The Hercules balance of $77.0 million had been due July 1, 2027, per the prior quarterly report. Because X4 showed the intent and ability to refinance before issuing its statements, the balance is classified as long-term debt rather than a current liability.
Cash, losses and the 4WARD trial
X4 held $187.7 million of cash, cash equivalents and short-term securities at September 30. It lost $56.6 million over the first nine months of 2026 and used $60.6 million in operations, and says that cash should fund operations and debt for at least 12 months.
Product sales of Xolremdi were $2.8 million in the third quarter against $1.6 million a year earlier. Total operating expenses fell to $22.9 million from $29.3 million.
In its pivotal 4WARD trial in chronic neutropenia, the FDA said in August that cutting enrollment from 176 to 126 participants keeps adequate power for the co-primary endpoints. X4 expects to finish enrolling by the end of 2026.
X4 expects to complete 4WARD enrollment by the end of 2026, and the market-value cash covenant begins October 1, 2027.
Sources
- 10-Q Filing — X4 Pharmaceuticals (XFOR) — SEC EDGAR
- 10-Q Filing — X4 Pharmaceuticals (XFOR), Q2 FY2026 filed 2026-08-06 (comparison basis) — SEC EDGAR
- 8-K Filing — X4 Pharmaceuticals, filed 2026-10-29 (Items 8.01, 9.01) — SEC EDGAR
- X4 Pharmaceuticals: Q3 Earnings Snapshot | 11alive.com — Associated Press
- X4 Pharmaceuticals Reports Third Quarter 2026 Financial — globenewswire.com
- X4 Pharmaceuticals to Participate in Guggenheim, Stifel, — globenewswire.com